Time is money, especially in the race to discover new anti-inflammatory drugs and bring them to market. Pharmaceutical companies typically spend years in the pre-clinical stage of the drug development process, incurring millions of dollars in costs. New medications for diseases such as heart disease, stroke, arthritis and multiple sclerosis could improve treatment for millions of people. Yet a key part of the discovery process — monitoring the movement and speed of white blood cells in living tissue — involves hours of tedious and often inherently flawed handwork.